During calorie reduction, protein intake often falls unintentionally
Analysis of commercial claims data covering approximately 50 million insured lives found GLP-1 users experienced: 44% fewer major cardiovascular-related hospitalizations 69% improvement in medical spend growth among diabetes-related GLP-1 users over 30 months 37% improvement in medical spend growth among weight-loss GLP-1 users over 18 months Researchers have also observed positive trends related to inflammatory conditions, cardiovascular disease, and other chronic health concerns
GLP-1 agonists are a different story
Many GLP-1 medications (Ozempic, Mounjaro) were first approved for diabetes treatment, then later approved for obesity under different brand names (Wegovy, Zepbound)
Their responses concern fiscal years 2024 and 2025, which covers a period of uncertainty for the programs
These interventions include routine visits to an optometrist (OD) or ophthalmologist (MD) (Pelletier 2009), exercising regularly (Munch 2013), avoiding smoking (Velilla 2013), reducing exposure to ultraviolet (UV) light (Sui 2012), controlling blood sugar (Diabetes Control and Complications Trial Research Group 1993) as well as blood pressure and blood lipid levels (UK Prospective Diabetes Study Group 1998
